期刊
DRUG DELIVERY
卷 28, 期 1, 页码 357-371出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10717544.2021.1879315
关键词
Targeted drug delivery; thrombolysis; ischemic stroke; nanothrombolysis; tissue plasminogen activator
资金
- National Natural Science Foundation of China [81971105]
- Jilin Province Department of Finance [JLSWSRCZX2020-0035]
Ischemic stroke, caused by sudden reduction in cerebral blood flow, is a major cause of severe disability and death globally. The use of tissue plasminogen activator (tPA) for thrombolysis treatment has limitations, but nanotechnology-based strategies have shown promise in improving thrombolytic efficacy and targeted delivery of thrombolytic agents.
Ischemic stroke is one of the major causes of severe disability and death worldwide. It is mainly caused by a sudden reduction in cerebral blood flow due to obstruction of the supplying vessel by thrombi and subsequent initiation of a complex cascade of pathophysiological changes, which ultimately lead to brain ischemia and even irreversible infarction. Thus, timely and effective thrombolysis therapy remains a mainstay for acute ischemic stroke treatment. Tissue plasminogen activator (tPA), the only thrombolytic agent approved globally, provides substantial benefits by exerting a fibrinolysis effect, recovering the blood supply in occluded vessels and, thereby, salvaging the ischemic tissue. However, the clinical application of tPA was limited because of a few unsolved issues, such as a narrow therapeutic window, hemorrhagic complications, and limited thrombolytic efficacy, especially, for large thrombi. With the prosperous development of nanotechnology, a series of targeted delivery strategies and nanocomposites have been extensively investigated for delivering thrombolytic agents to facilitate thrombolysis treatment. Excitingly, numerous novel attempts have been reported to be effective in extending the half-life, targeting the thrombus site, and improving the thrombolytic efficacy in preclinical models. This article begins with a brief introduction to ischemic stroke, then describes the current state of thrombolysis treatment and, finally, introduces the application of various nanotechnology-based strategies for targeted delivery of thrombolytic agents. Representative studies are reviewed according to diverse strategies and nano-formulations, with the aim of providing integrated and up-to-date information and to improve the development of thrombolysis treatment for stroke patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据